Madison Sustainable Equity Fund highlighted stocks like Equifax Inc. (NYSE:EFX) in the Q3 2024 investor letter. Equifax Inc. ...

In a report released today, Andrew Steinerman from J.P. Morgan maintained a Buy rating on Equifax (EFX – Research Report), with a price target ...

Over 40% of participants treated with EFX 50mg for 96 weeks, compared with 0% for placebo, showed regression of liver ...

Equifax Inc. (NYSE:EFX) shareholders might be concerned after seeing the share price drop 17% in the last quarter. But at least the stock is up over the last five years. However we are not very ...

JPMorgan analyst Andrew Steinerman lowered the firm’s price target on Equifax (EFX) to $283 from $304 and keeps an Overweight rating on the ...

Enerflex Ltd. (TSE:EFX – Get Free Report)’s share price hit a new 52-week high during mid-day trading on Monday after Acumen Capital raised their price target on the stock from C$12.00 to C$15.00. The ...

On Friday, Equifax Inc (EFX) stock saw a decline, ending the day at $248.27 which represents a decrease of $-13.94 or -5.32% from the prior close of $262.21. The stock opened at $257.81 and touched a ...

Enerflex (TSE:EFX – Free Report) had its target price raised by BMO Capital Markets from C$11.00 to C$15.00 in a report ...

First patients dosed in Phase 3 SYNCHRONY Outcomes study of lead candidate efruxifermin (EFX) in patients with compensated ...

SOUTH SAN FRANCISCO - Akero Therapeutics, Inc. (NASDAQ:AKRO), a clinical-stage biotechnology company, announced significant clinical outcomes from its Phase 2b HARMONY study, evaluating the efficacy ...

The study revealed that after 96 weeks of EFX treatment, over 40% of participants exhibited regression of liver fibrosis, a key indicator of MASH progression. This includes improvements in liver ...